ALDEYRA THERAPEUTICS INC (ALDX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for ALDX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ALDX | Director | 60 | ["Chief Business Officer of Anaveon AG","Chairman of the supervisory boards of Nanobiotix SA and BioConnection BV","President & CEO of OrphoMed, Inc.","Executive Vice President & Chief Strategy Officer at Mallinckrodt Pharmaceuticals plc","Head of global health at the World Economic Forum","President of Reckitt Benckiser Pharmaceuticals, Inc.","Executive roles at Merck KGaA, Novartis, and Wyeth","Healthcare strategy managing consultant at Towers Perrin","Medical officer with the United States Navy"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Dr. Phillips has served as a member of our Board of Directors since May 2009. Dr. Phillips served as Chief Business Officer of Anaveon AG from May 2022 to 2026. Dr. Phillips currently serves as the Chairman of the supervisory boards of Nanobiotix SA and BioConnection BV. Prior to that, he was President & CEO of OrphoMed, Inc. from 2018 to 2022 and Executive Vice President & Chief Strategy Officer at Mallinckrodt Pharmaceuticals plc (now Keenova) from 2013 to 2018. Previously, Dr. Phillips held the dual roles of president, U.S. surgical and pharmaceuticals, and global head of pharmaceuticals at Bausch & Lomb. Additionally, he has served as the head of global health at the World Economic Forum in Geneva and was president of Reckitt Benckiser Pharmaceuticals, Inc. (now Indivior). He has also held executive roles at Merck KGaA, Novartis, and Wyeth (now Pfizer). He was a healthcare strategy managing consultant at Towers Perrin (now Willis Towers Watson) and a medical officer with the United States Navy, from which he was honorably discharged as a lieutenant commander. Dr. Phillips was educated at the University of Pennsylvania, where he received an M.D. (Alpha Omega Alpha) from the School of Medicine, an M.B.A. from the Wharton School, and B.A. (summa cum laude, Phi Beta Kappa) in biochemistry from the College of Arts and Sciences. He completed postgraduate medical education at Naval Medical Center San Diego and maintains an active medical license. Dr. Phillips extensive knowledge of our business and history, and his experience in pharmaceutical strategy at multiple multinational companies, contributed to our conclusion that he should serve as a director of our company.